Agios Pharmaceuticals (AGIO) Retained Earnings (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Retained Earnings data on file, last reported at -$761.5 million in Q2 2026.

• Quarterly Retained Earnings fell 117.43% year-over-year to -$761.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$761.5 million (down 117.43% YoY) and the FY2025 annual result came in at -$561.7 million, down 277.18% from the prior year.
• Retained Earnings retreated to -$761.5 million in Q2 2026, from -$660.8 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$52.4 million in Q3 2024 to a low of -$1.0 billion in Q2 2024.
• A 5-year average of -$533.6 million and a median of -$529.3 million in 2022 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings tumbled 1181.15% — and 2024, when it soared 92.79%.
• Tracing AGIO's Retained Earnings over 5 years: stood at -$470.6 million in 2022, then tumbled by 74.82% to -$822.6 million in 2023, then jumped by 81.9% to -$148.9 million in 2024, then slumped by 277.18% to -$561.7 million in 2025, then tumbled by 35.57% to -$761.5 million in 2026.
• The last three Retained Earnings figures came in at -$761.5 million (Q2 2026), -$660.8 million (Q1 2026), and -$561.7 million (Q4 2025), per Business Quant data.